Epidermal growth factor/TNF-α transactivation modulates epithelial cell proliferation and apoptosis in a mouse model of parenteral nutrition

Yongjia Feng and Daniel H. Teitelbaum

Section of Pediatric Surgery, Department of Surgery, the University of Michigan Medical School and the C. S. Mott Children’s Hospital, Ann Arbor, Michigan

Submitted 8 April 2011; accepted in final form 9 November 2011

EGF- and tumor necrosis factor-α (TNF-α) signaling are critical for effective proliferative and apoptotic actions; however, little is known about the codependency of these signaling pathways in the intestinal epithelium. Because total parenteral nutrition (TPN) is associated with loss of intestinal epithelial cell (IEC) proliferation and increased apoptosis, we utilized a mouse model to explore these transactivation pathways in small bowel epithelium. Mice underwent intravenous cannulation and were given enteral nutrition or TPN for 7 days. Outcomes included IEC proliferation, apoptosis, and survival. To address transactivation or dependence of EGF and TNF on IEC physiology, TNF-α receptor knockout (KO) mice, TNFR1-KO, R2-KO, or R12R2-double KO, were used. Exogenous EGF and pharmacological blockade of ErbB1 were performed in other groups to examine the relevance of the ErbB1 pathway. TPN increased IEC TNFR1 and decreased EGF and ErbB1 abundance. Loss of IEC proliferation was prevented by exogenous EGF or blockade of TNFR1. However, EGF action was prevented without effective TNFR2 signal. Also, blockade of TNFR1 could not prevent loss of IEC proliferation without effective ErbB1 signaling. TPN increased IEC apoptosis and was due to increased TNFR1 signaling. Exogenous EGF or blockade of TNFR1 could prevent increased apoptosis, and both pathways were dependent on effective ErbB1 signaling. Exogenous EGF prevented increased apoptosis in mice lacking TNFR2 signaling. TPN mice had significantly decreased survival vs. controls, and this was associated with the TNFR1 signaling pathway. We concluded that these findings identify critical mechanisms that contribute to TPN-associated mucosal atrophy via altered TNF-α/EGF signaling. It emphasizes the importance of both TNFR1 and TNFR2 pathways, as well as the strong interdependence on an intact EGF/ErbB1 pathway.

Tumor necrosis factor

Total parenteral nutrition (TPN) is vital for the support of patients who cannot tolerate enteral nutrition. However, TPN has been associated with a number of clinical problems including a decline in intestinal epithelial cell (IEC) proliferation and increased apoptosis, and together these processes can lead to intestinal mucosal atrophy (19, 23). These changes may have clinical implications, as TPN in humans is associated with increased septic and infectious complications (19). The mechanisms contributing to atrophy are not completely clear. Using a mouse model, our laboratory previously showed that TPN led to decreased p-Akt expression (8, 9). Epidermal growth factor (EGF) is a major upstream factor that can drive phosphatidylinositol 3-kinase (PI3K)/P-Akt signaling (26). EGF signaling occurs via one of four tyrosine kinase receptors, namely ErbB1–4, and these receptors are essential for modulating cell survival, proliferation, and differentiation in various tissues (4). ErbB1 has been shown to be critical for mediating both IEC proliferation and antiapoptotic actions (10). Recent evidence demonstrates that EGF signaling is dependent on intact tumor necrosis factor (TNF-α) signaling (29).

The cytokine TNF-α is produced as a 26-kDa homotrimeric, transmembrane precursor that is cleaved by metalloproteinases into a soluble 17-kDa polypeptide (2, 3, 24). TNF-α binds to two distinct transmembrane receptors: the 55-kDa low-affinity TNF receptor (TNFR1), and the 75-kDa high-affinity TNFR2 (13, 15, 20). Normally the proinflammatory action via TNFR1 signaling is balanced by a protective action via TNFR2 (6).

Recently, it has been appreciated that TNF-α and ErbB family can transactivate a number of similar intracellular pathways including Akt and MAP/ERK (10, 21, 32). TNF-α has typically been viewed as mediating inflammation and apoptosis; however, many of these actions are balanced or modulated via EGF signaling. Loss of EGFR expression or inhibition of its kinase activity lead to increased TNF-induced apoptosis (32). Additionally, IEC apoptosis predominates in the absence of effective EGFR signaling, presumably via unopposed TNF signaling. Conversely, TNF-α can also sustain IEC proliferation (15), upregulate ErbB2, as well as promote EGFR phosphorylation (21, 32). What is not known within the gastrointestinal epithelium is the relative importance of the TNFR1 vs. TNFR2 signaling pathways and transactivation of TNF signaling via EGF.

How these changes in IEC proliferation/apoptosis occur vary greatly depending on tissue type and duration of stimuli. Interestingly, our mouse TPN model represents a state of increased TNF-α expression, as well as increased IEC apoptosis and reduced IEC proliferation (30, 33, 34). This model, therefore, offers a unique opportunity to study mechanisms contributing to villus atrophy in the absence of overt inflammatory changes or epithelial destruction in inflammatory bowel disease models. These observations led us to hypothesize that derangement in the TNF-α/EGF transactivation signaling machinery mechanistically contributes to TPN-associated mucosal atrophy.

The present study demonstrates for the first time key mechanisms responsible for TPN-associated atrophy, including increased TNF-α signaling via TNFR1 and a TNF-α-independent mechanism via loss of EGF signaling. Conversely, exogenous EGF can prevent the marked increase in TNFR1 occurring with TPN. We further demonstrate the novel finding that EGF signaling was partly dependent on an intact TNFR2 pathway to maintain IEC proliferation. Additionally, preven-
were randomized to enterally fed control or TPN groups. Mice were housed in metabolic cages to prevent coprophagia. Studies conformed with C57BL6J background (Jackson) were also studied. Mice were matched and age-matched adult male TNFR1R2 double knockout (DKO; Tnfrsf1atm1Imx Tnfrsf1btm1Imx), and TNFR2-KO mice (R2KO Tnfrsf1atm1Imx Tnfrsf1btm1Imx), with C57Bl/6J background (Jackson) were also studied. Mice were housed in metabolic cages to prevent coprophagia. Studies conformed to approval by our University Committee on Use and Care of Animals; all the procedures were in accordance with our Institutional Animal Care and Use Committee (IACUC) approval. Animals. C57BL/6 male, specific pathogen-free 10-wk-old mice (Jackson Laboratory, Bar Harbor, ME) were maintained under controlled temperature, humidity, and light conditions. Body weight-matched and age-matched adult male TNFRII2 double knockout (DKO; Tnfrsf1atm1Imx Tnfrsf1btm1Imx), TNFR1-KO (Tnfrsf1atm1Imx Tnfrsf1btm1Imx), and TNFR2-KO mice (R2KO Tnfrsf1atm1Imx Tnfrsf1btm1Imx), with C57Bl/6J background (Jackson) were also studied. Mice were administered via oral gavage, twice daily, starting 3 days prior to cannulation (18). ErbB1 inhibitor, gefitinib (2.5 mg/ml in 1% aqueous Tween-80, 200 μl saline; Sigma-Aldrich, St. Louis, MO) via oral gavage, starting 1 day postcannulation. EGF was administered via oral gavage twice daily, starting 3 days before intravenous cannulation and continuing until mice were killed (12, 17, 25). Nitrogen and energy delivery was matched between controls and enteral controls (Fig. 1, A and B). In contrast, TNFR2 expression did not significantly change. Confirmation of the specificity of the antibodies was performed by using exogenous EGF at various concentrations, and the results were expressed as number of PCNA-positive cells per villi using a mean of 10 villi per mouse.

**RESULTS**

TPN administration increased intestinal IEC TNF-α and TNFR1 abundance. Our group previously demonstrated TPN-associated increased mucosal TNF-α mRNA expression (31). To examine this further, we showed that IEC-membrane-bound pro-TNF-α significantly increased with TPN (control: 0.18 ± 0.09 vs. TPN: 0.43 ± 0.16, P < 0.05) (Fig. 1A). Additionally, expression of both TNFR1 mRNA and protein increased 1.6-fold and sevenfold, respectively, in wild-type TPN mice versus enteral controls (Fig. 1, B and C). In contrast, TNFR2 expression did not significantly change. Confirmation of the specificity of the antibodies to TNFR1 and TNFR2 is shown in Fig. 1D.

We next assessed the effects of exogenous EGF on TNF-α and its receptors. EGF given to TPN mice almost completely reversed the increase in TNFR1, whereas, at the protein level,
EGF led to markedly increased TNFR2 (Fig. 1C). This marked difference in response to exogenous EGF on TNFR1 and TNFR2 suggested distinct roles for TNF-α/EGF transactivation between these two receptors.

Abundance of ErbB ligands decreased in wild-type TPN mice. mRNA expression of jejunal mucosal ErbB ligands EGF, transforming growth factor (TGF)-α, amphiregulin, heparin-binding EGF-like growth factor (HBEGF), epiregulin, and...
neuregulins (Nrg1, 3, 4) were all significantly decreased with TPN (Fig. 2). We next examined whether ligand loss could be prevented with exogenous EGF but found that only the TPN-associated decline in Nrg4 was significantly reversed (Fig. 2). Interestingly, abrogation of TNF signaling during TPN using TNFR1R2-DKO mice prevented the decline in EGF, TGF-α, amphiregulin, betacellulin, and Nrg3 expression compared with wild-type TPN mice, and values in DKO mice were not significantly different than enteral controls. This suggests that the increase in TNF-α signaling with TPN accounts for much of the decline in EGF ligand expression.

TPN led to a decline in ErbB1 expression. TPN led to a significant decline in expression of ErbB1 (3-fold mRNA; Fig. 3A). ErbB1 immunofluorescent staining was predominately located in crypts and the lower one-third of villi (Fig. 3B). A marked decrease in fluorescence intensity was noted in wild-type, TPN mice. Additionally, in controls, ErbB1 was located on the cell membrane; however, with TPN administration both ErbB1 density declined and an internalization of ErbB1 were observed.

Immunoblot analysis of IEC isolates confirmed that ErbB1 protein expression significantly decreased (>10-fold) in wild-
type TPN mice vs. controls (Fig. 3, C and D). Exogenous EGF in TPN mice prevented the loss of abundance of ErbB1. Interestingly, in TNF-α receptor-KO mice, a distinct difference in ErbB family expression was observed. TNFR1R2-DKO TPN mice maintained control levels of ErbB1, whereas TNFR1-KO TPN mice only partially prevented ErbB1 loss, and TNFR2-KO TPN mice had levels similar to wild-type TPN mice (Fig. 3D). Quite interestingly, these results show that aberrations in TNF signaling with TPN administration contributed to the TPN-associated loss of ErbB1. These data suggest that TNFR1 signaling directly leads to a loss of ErbB1 abundance in this TPN model.

TPN downregulated phospho-Akt abundance and altered other downstream intracellular signals. We have previously identified a loss of p-Akt expression with TPN administration (8) and confirmed this in the present study (Fig. 4B). Interestingly, in the present study, loss of p-Akt was partially prevented in TPN + EGF mice. More strikingly, TNFR1R2-DKO or TNFR1-KO TPN-mice also prevented p-Akt loss to an even greater degree (Fig. 4B). No change in p-Akt expression was found in TNFR1-KO TPN mice (Fig. 4B).
noted in TNFR2-KO TPN mice (Fig. 4B). These results suggest that TNF-α signaling via TNFR1 is responsible for loss of PI3K/p-Akt signaling with TPN administration.

In contrast to the results with p-Akt, phospho-ERK (MAPK/ERK) expression was upregulated with TPN (Fig. 4A). Neither exogenous EGF nor use of TNFR-KO mice prevented this increased expression. To further investigate the downstream signaling involved with TPN, we measured phospho-p38 (pp38), phospho-SAPK/JNK (P-SAPK/JNK), and IKK expression in IECs (Fig. 4C–E). TPN resulted in increased pp38 and p-JNK1/JNK2 expression in wild-type mice, whereas TPN + EGF prevented these increases. Upregulation of pp38 was also prevented in TNFR1R2-DKO and TNFR1-KO mice receiving TPN. Interestingly, only the upregulation of phospho-JNK2 expression was prevented in TNFR1R2-DKO and TNFR1-KO TPN mice, whereas ERK and phospho-JNK1 remained unchanged (Fig. 4D and E).

TPN-associated decline in IEC proliferation is due to loss of EGF and increased TNF-α signaling through TNFR1. Baseline apoptosis rates were similar in all chow-fed transgenic groups compared with wild-type mice (data not shown). TPN administration led to significantly increased small bowel IEC apoptosis (Fig. 6A–B). Active caspase-3 staining was predominately located in the villi and to a lesser extent in crypts. The number of active caspase-3 enterocytes significantly decreased in TPN + EGF mice (to control levels). Even with low EGF levels in TPN mice, reduction in IEC apoptosis was also found in TNFR1R2-DKO and TNFR1-KO TPN groups. Very interestingly, loss of TNFR2 in TPN mice led to significantly higher rates of IEC apoptosis than in wild-type-TPN mice, almost all of which occurred in the villi. Removal of TNFR1 led to an increase in TNFR2 (Fig. 7A, iii), whereas use of TNFR2-KO TPN mice led to an increase in TNFR1 (Fig. 7A, ii). Together, this strongly suggests that the balance of TNFR1 and TNFR2 signaling is critically important for preventing apoptosis.

Bax mRNA expression was upregulated, and Bcl-2 mRNA expression was downregulated in wild-type TPN mice (data not shown). Bax protein abundance increased twofold in wild-type TPN mice, and this was completely prevented by administration of EGF (Fig. 6D). TPN in TNFR1R2-DKO and

---

![Fig. 4](http://ajpgi.physiology.org/) Summary of Erk is not shown, as no differences between TPN groups were detected. Protein derived from IEC isolates of small bowel from indicated study groups. A: representative immunoblots for Akt, Erk, p38, and JNK for active forms and total expression of each protein. B: p-Akt abundance expressed as a ratio to total Akt expression. C: phosphorylated p38 (pp38) abundance expressed as a ratio to β-actin. D and E: p-JNK1 and p-JNK2 abundance expressed as a ratio to total JNK1 and JNK2, respectively. For representative immunoblots, a minimum of 6 experiments and images were used for each selection. Results are the means ± SD and N = 6–7 per group. Compared with WT TPN: #P < 0.05; **P < 0.001.
TNFR1-KO mice, but not TNFR2-KO mice, also prevented this increase in Bax. Bcl-2 protein expression declined threefold in wild-type TPN mice vs. controls (Fig. 6E). Markedly increased levels of Bax and decreased levels of Bcl-2 were observed in TNFR2-KO TPN mice, suggesting that Bax and Bcl-2 levels may contribute to the much higher apoptosis rates in TNFR2-KO mice. Although variations in differences in expression were seen between mRNA and protein expression,
Bax and Bcl-2 protein values returned to control values in TNFR1R2-DKO and TNFR1-KO TPN groups. Furthermore, EGF partially prevented Bax increases and completely returned Bcl-2 levels to control values (Fig. 6C). This suggests one potential mechanism for how EGF and blockade of TNFR1 mediate their prevention of IEC apoptosis potentially through the Bcl-2 family.

ErbB1 signaling must occur to allow normal epithelial cell proliferation, and blockade of ErbB1 signaling markedly increased apoptosis with TPN. To further investigate the interdependence of these signaling pathways, EGFR was blocked with the EGFR-specific kinase inhibitor gefitinib (Fig. 7). Gefitinib given to TPN mice resulted in a marked decline in IEC proliferation compared with control groups (Fig. 7, B–D), similar to wild-type TPN group. Although blockade of TNFR1 prevented loss of proliferation and increase in IEC apoptosis with TPN, this was prevented with concomitant gefitinib treatment and was associated with reduced ErbB1 expression (Fig. 7A, i) and increased TNFR1 expression (Fig. 7A, ii). This suggested that the protection of IEC proliferation and apoptosis from blockade of TNFR1 was highly dependent on EGF signaling. Interestingly, although EGF treatment could also prevent loss of proliferation in wild-type TPN mice, this prevention was observed in the TNFR1R2 DKO TPN group, but not in TNFR2-KO mice (Fig. 7, B–D), where there was increased TNFR1 expression in TNFR2KO TPN group (Fig. 7A, iii) and increased TNFR2 expression in TNFR1KO TPN group (Fig. 7A, iv). This demonstrated the critical role of the balance of TNFR1 and TNFR2 pathway for maintaining IEC proliferation. As shown in Fig. 6, A and B, TNFR2-KO TPN mice had profound rates of IEC apoptosis. Interestingly, the importance of EGF-mediated prevention of apoptosis is further demonstrated by the ability of exogenous EGF to counter this marked increase in IEC apoptosis seen in TNFR2-KO TPN mice (Fig. 7E). This may be via prevention in the associated loss of EGFR with TPN (Fig. 7A, i).

As proliferation rates could markedly vary with these transgenic mice, as well as with exogenous EGF and gefitinib treatment, Fig. 8 shows the changes in PCNA staining in Sham (enterally fed) control mice. The results show very little change in number of PCNA cells in any of these groups of control mice. To further insure that baseline abundance of TNF receptors was not influenced in the experiments, as well as EGF ligands, Table 2 shows alterations in these...
respective abundances with sham mice given either gefitinib or exogenous EGF. Note that abundances of EGF and Nrg3 were increased with exogenous EGF, a finding previously described (36); however, the majority of abundances remain quite stable.

Mouse survival with TPN improves with EGF or blockade of TNFR1 and adversely affected with loss of TNFR2. TPN in a clinical setting is associated with increased morbidity and mortality (19, 22), and this correlates in our mouse model with a high rate of septicemia and mortality (16, 29). Survival curves were generated to address whether modulation of EGF/TNF signaling impacted mortality (Fig. 9). Survival was 100% at 7 days in control mice, whereas 30% of mice died before 7 days in wild-type TPN mice (Fig. 9A, \( P = 0.046 \)). In the TNFR1-KO TPN group, a 100% survival was observed (\( P = 0.058 \) vs. wild-type TPN). The TPN/EGF group showed a moderate improvement in outcome compared with wild-type TPN mice. However, the survival of the TNFR2-KO TPN group approached that of wild-type TPN mice, whereas the combined TNFR1R2-DKO TPN group had a much worse outcome compared with TNFR1-KO TPN mice (Fig. 9B), suggesting that blockade of the TNFR2 signaling pathway adversely affected survival. These data suggest that an imbalance of TNFR1 vs. R2 signaling affects survival and may relate to the marked increase in apoptosis that occurred in this TPN group. The survival rate in wild-type TPN mice was 70%; however, this decreased to 33% for wild-type TPN mice receiving gefitinib (Fig. 9C). Interestingly, although administration of gefitinib eliminated the benefits to IEC proliferation and apoptosis in TNFR1-KO mice, it did not adversely affect survival in this strain (Fig. 9C). The mechanisms accounting for this preserved survival may relate to other factors, potentially preserved epithelial barrier function, and will need to be examined in future studies.

TPN-associated mucosal atrophy was prevented by exogenous EGF, as well as by blocking the TNFR1 signaling pathway. Histological appearance of jejunal specimens are shown in Fig. 10. TPN resulted in a loss of villus length and crypt depth compared with enteral controls. Administration of EGF to TPN mice prevented loss of villus height but did not significantly impact loss of crypt depth. Use of TNFR-KO mice showed that blockade of the TNFR2 pathway failed to impact morphology, whereas blockade of the TNFR1 pathway significantly prevented much of the loss of villus height. Combining EGF administration and TNFR1R2-DKO mice resulted in virtually normal (control) histological appearance (crypt depth and villus height).

![Image](http://ajpgi.physiology.org/)
DISCUSSION

Most of the interactions between TNF-α and EGF have been studied in vitro or in models of inflammatory bowel disease (IBD). Although these are quite informative, the use of this TPN model allows for an examination of these factors in intact intestine and during a process of crypt-villus architecture remodeling. In the present study, we showed that TNFR1 and TNF-α were significantly upregulated on small IEC during TPN, whereas ErbB1 was downregulated. This suggested that removal of enteral nutrition results in a proinflammatory state. By using TNFR1/R2-KO mice and blocking ErbB1, we showed that TNFR1 signaling was proapoptotic, whereas TNFR2 had distinct proproliferation effects, demonstrating that a critical balance of the TNFR1 and TNFR2 pathways is needed for IEC homeostasis. Furthermore, elimination of TNFR1 prevented the TPN-associated loss of IEC proliferation; however, this was strongly codependent on effective EGF signaling. Although administration of EGF could not prevent the loss of IEC proliferation in TNFR2-KO TPN mice, this may have been due to a dominant expression of TNFR1. With removal of both TNFR1 and TNFR2, exogenous EGF completely prevented the loss of proliferation in TPN mice. Interestingly, despite loss of TNFR2 signaling leading to a marked increase in apoptosis, the antiapoptosis effect of EGF was not dependent on TNFR2 signaling. A summation of the complex interactions of these two signaling pathways is shown in Fig. 11.

Table 2. Alternations in abundance of TNF receptors

<table>
<thead>
<tr>
<th></th>
<th>Sham + Gefitinib</th>
<th>Sham + EGF</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amphiregulin(10-2)</td>
<td>3.25 ± 1.64</td>
<td>3.67 ± 0.69</td>
<td>ns</td>
</tr>
<tr>
<td>EGF(10-3)</td>
<td>3.99 ± 2.04*</td>
<td>9.76 ± 4.52</td>
<td>P = 0.014</td>
</tr>
<tr>
<td>TGFR(10-3)</td>
<td>12.96 ± 2.51</td>
<td>12.66 ± 2.95</td>
<td>ns</td>
</tr>
<tr>
<td>HBEGF(10-2)</td>
<td>7.52 ± 2.71</td>
<td>9.21 ± 1.85</td>
<td>ns</td>
</tr>
<tr>
<td>Epiregulin(10-3)</td>
<td>7.72 ± 2.14</td>
<td>8.40 ± 1.83</td>
<td>ns</td>
</tr>
<tr>
<td>Betacellulin(10-3)</td>
<td>4.47 ± 1.06</td>
<td>4.53 ± 2.24</td>
<td>ns</td>
</tr>
<tr>
<td>Nrg1(10-3)</td>
<td>4.24 ± 0.72</td>
<td>4.88 ± 1.42</td>
<td>ns</td>
</tr>
<tr>
<td>Nrg3(10-4)</td>
<td>19.3 ± 8.19</td>
<td>28.8 ± 6.25</td>
<td>P = 0.07</td>
</tr>
<tr>
<td>Nrg4(10-4)</td>
<td>4.38 ± 1.96</td>
<td>4.58 ± 1.40</td>
<td>ns</td>
</tr>
<tr>
<td>ErbB1(10-3)</td>
<td>5.43 ± 1.21</td>
<td>7.64 ± 3.10</td>
<td>ns</td>
</tr>
<tr>
<td>TNFR1(10-2)</td>
<td>2.59 ± 0.43</td>
<td>2.17 ± 0.33</td>
<td>ns</td>
</tr>
<tr>
<td>TNFR2(10-2)</td>
<td>4.20 ± 1.42</td>
<td>4.44 ± 1.92</td>
<td>ns</td>
</tr>
</tbody>
</table>

Values are means ± SE. *P < 0.01; ns, no significant difference.

Intestinal IEC growth is critical for adaptive proliferation after intestinal resection (18, 28) and response to damage (5), and EGFR (ErbB-1) is a major mediator of these responses (27). In our study, TPN resulted in a marked loss of ErbB1 and several ligands. Exogenous EGF partially reversed TPN-associated TNFR1 upregulation and partially prevented ErbB1 downregulation. This resulted in a prevention of increased pp38 and p-SAPK/JNK expression, preserved IEC proliferation, and returned apoptosis to control rates. Furthermore, the marked shift in Bcl-2 and Bax expression may be the common downstream signals to contributing mechanistically to these observed changes, as has been previously suggested (14). This common response suggests that the mechanistic cause of mucosal atrophy during TPN is due to downregulation of ErbB1 and/or upregulation of TNFR1 signaling; both of which may converge via phosphorylation of p38 and SAPK/JNK signaling.

Fig. 9. Kaplan-Meier survival curves for each study group; study N per group and survival percentages for each group are shown. TPN administration reduced survival percentages, and this was improved with either EGF supplementation, or with elimination of TNFRs, with 100% survival in the TNFR1-KO TPN group. A: comparison between control and TPN groups. B: comparison between TPN + EGF and TNFR-KO groups. C: comparison of survival curves among other study groups from Fig. 7. Survival was significantly lower in TPN vs. control group (P = 0.046). Survival approached significant difference for TNFR1-KO TPN vs. WT TPN groups (P = 0.058).
This is further supported by the findings wherein TNFR1-KO TPN mice did not regain normal IEC proliferative levels when EGF signaling was blocked. EGF administration protected the TPN-associated loss of p-Akt abundance; similar results were observed in mice without TNFR1, but not in TNFR2-KO TPN mice. This suggested that EGF and TNFR1 may interact through a common intracellular path via p-Akt to affect IEC proliferation and apoptosis. Conversely, TNFR2 has been reported to mediate IEC proliferation (1); however, in our study, we did not detect any change in the expression of TNFR2 between control and TPN mice; however, in TPN + EGF mice there was an increase in TNFR2 protein expression and a complete recovery of IEC proliferation. The fact that blocking TNFR1 (TNFR1-KO) signaling while preserving TNFR2 similarly prevented loss of IEC proliferation suggested that preserved TNFR2 signaling has a key role in driving enterocytic proliferation. Further support for the role of TNFR2 signaling in IEC proliferation was seen by the failure to alter IEC proliferation in TNFR2-KO TPN mice compared with wild-type TPN mice. Such results are consistent with previous in vivo studies of septic shock. (6)

IEC apoptosis was also significantly increased with TPN. It was interesting that exogenous EGF or removal of TNFR1 signaling were very effective at preventing this rise in apoptosis. Furthermore, these results correspond to other proapoptotic signals in small bowel IECs, such as resection-induced apoptosis (18). Conversely and even more dramatic was the observation of a marked increase in IEC apoptosis in TNFR2-KO TPN mice vs. wild-type TPN mice. This finding suggests that TNFR2 signaling in IECs has a particularly strong antiapoptotic function and that a balance between TNFR1, TNFR2, and EGF signaling is critical in modulating IEC apoptotic rates. The fact that Bax was increased and Bcl-2 was decreased in the TNFR2-KO group suggests a possible mechanism for this antiapoptotic action.

In our present study, blockade of ErbB1 signaling significantly decreased survival in TPN mice and was associated with a significant increase in IEC apoptosis and decreased proliferation. This suggests that loss of ErbB1 signaling is a key factor in the development of TPN-associated atrophy. Additionally, removing the TNFR1 signaling pathway could not prevent this observed loss of proliferation without an intact ErbB1 path. The decreased abundance of ErbB1 in wild-type TPN mice increased with EGF supplementation, and this may be one way in which EGF prevents TPN-
associated atrophy, potentially via ErbB1-ErbB2 heterodimerization. Frey et al. (10) reported elevated ErbB4 levels in inflammatory bowel disease; as this disease process is characterized by an increase in TNF-α, future work will be needed to examine the interaction of ErbB1 and the other ErbB family members, ErbB2, 3 and 4, in this TPN model. Additionally, EGF/TNF signaling may affect the immunocyte infiltration into the small bowel of TPN mice and will also need to be examined in future studies.

In conclusion, TPN led to an increase in IEC apoptosis and a decline in proliferation. This study demonstrates that this occurs through increased TNF-α signaling and loss of ErbB signaling. EGF and TNF-α signaling were tightly interdependent, and TPN-associated atrophy may occur via both an imbalance of TNF-α receptors and decline in EGF. The TPN model is novel in that previous attempts to understand this complex TNF/EGF interrelation have been confined to either in vitro settings or use of IBD models, which may have confounding processes of severe epithelial destruction, a finding not observed in the TPN model. A greater understanding of this process may have tremendous benefit to the safety of clinical delivery of TPN.
GRANTS
This work was supported by National Institutes of Health 2R01AI-44076-12. The work was also supported with the help of the National Cancer Institute through the University of Michigan’s Cancer Center Support Grant (5 P03 CA46592).

DISCLOSURES
No conflicts of interest, financial or otherwise, are declared by the authors.

REFERENCES
4. Ebach DR, Riehl TE, Stenson WF.